KILITCH DRUGS INDIA LTD Intrinsic Value
KILITCH · Healthcare · Current price ₹182.19
Is KILITCH DRUGS INDIA LTD undervalued?
DocStoX estimates the fair value of KILITCH DRUGS INDIA LTD at ₹138 per share, versus the current market price of ₹182. That puts the stock about -24.1% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹80), Relative P/E (₹262), Graham floor (₹125). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹80 (bear) to ₹138 (base) to ₹262 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹182 versus an intrinsic value of ₹138, KILITCH DRUGS INDIA LTD currently offers -24.1% of negative margin (i.e. a premium).
More on KILITCH DRUGS INDIA LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.